Forchlorfenuron (FCF) is a synthetic cytokinin that inhibits septins and exhibits anti-parasitic, anticancer, and anti-angiogenic activities. Forchlorfenuron is also a plant growth regulator. Cytotoxicity of forchlorfenuron and its metabolites are tested through Sulforhodamine B assays against CHO cells. Forchlorfenuron exhibits significant cytotoxicity against CHO cells with an IC50 of 12.12±2.14 μM.
In live mammalian cells, FCF dampens septin dynamics and induces the assembly of abnormally large septin structures. FCF has a low level of cytotoxicity, and these effects are reversed upon FCF washout. Significantly, FCF treatment induces mitotic and cell migration defects that phenocopy the effects of septin depletion by small interfering RNA. FCF targets the filamentous assembly of divergent septin isoforms (e.g. Cdc3/10/11/12 (42), SEPT2, SEPT7) reversibly and across species.
Forchlorfenuron (FCF) has low oral toxicity in rats with an LD50 of 4940 mg/kg bw in male rats and 4899 mg/kg bw in females.
Cell Experiment | |
---|---|
Cell lines | HeLa or MDCK cells |
Preparation method | HeLa or MDCK cells are plated overnight on collagen-coated 35-mm tissue culture dishes and then treated with DMSO or FCF for 4 h. Cells are trypsinized, resuspended in DMEM supplemented with 10% FBS, and mixed in a 1:1 ratio with trypan blue at room temperature for 1 min. Blue and non-blue cells are counted using a hemocytometer. |
Concentrations | 6.25-500 μM |
Incubation time | 4 h |
Animal Experiment | |
---|---|
Animal models | toxicity test of forchlorfenuron in rats |
Formulation | - |
Dosages | 4940 mg/kg bw in male rats and 4899 mg/kg bw in females |
Administration | oral |
Molecular Weight | 247.68 |
Formula | C12H10ClN3O |
CAS Number | 68157-60-8 |
Form | Solid |
Solubility (25°C) | DMSO: 30 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Products |
---|
Izeltabart
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models. |
Cofetuzumab
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
M3554 (anti-GD2 ADC)
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity. |
OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.